SuperworthSarepta Therapeutics PE ratio SRPT
Share price divided by earnings per share over the last twelve months, since 2010.
- Today, Oct 23, 2026
- n/m
- losses over the last year
- Last meaningful
- 32.1×
- May 2025
- Earnings per share, 12 months
- −$2.90
- to Jun 30, 2026
- Share price
- $17.73
- Oct 23, 2026
- Peer median
- 14.1×
Sarepta Therapeutics has no meaningful PE ratio today: it lost $2.90 a share over the last twelve months, and a PE needs earnings.
It was last meaningful in May 2025, at 32.1×.
It has had no meaningful PE for most of its history, so the chart below shows the earnings per share a PE divides the price by.
Earnings per share over time
A PE divides the share price by these earnings. While they were a loss or a sliver, the PE meant nothing, so this chart shows the earnings themselves.
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$8.44 | −526% |
| FY2024 | $1.98 | n/a |
| FY2023 | −$6.15 | n/a |
| FY2022 | −$8.03 | n/a |
| FY2021 | −$5.14 | n/a |
| FY2020 | −$7.06 | n/a |
| FY2019 | −$9.67 | n/a |
| FY2018 | −$5.42 | n/a |
| FY2017 | −$0.81 | n/a |
| FY2016 | −$5.46 | n/a |
| FY2015 | −$5.19 | n/a |
| FY2014 | −$3.39 | n/a |
| FY2013 | −$3.39 | n/a |
| FY2012 | −$4.96 | n/a |
| FY2011 | −$0.06 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.05 | −103% | −$2.90 | |
| Q1 FY26 | $2.88 | n/a | −$0.96 | |
| Q4 FY25 | −$3.93 | −428% | −$8.44 | |
| Q3 FY25 | −$1.80 | −629% | −$3.31 | |
| Q2 FY25 | $1.89 | +2600% | −$1.17 | |
| Q1 FY25 | −$4.60 | −1343% | −$2.99 | |
| Q4 FY24 | $1.20 | +173% | $1.98 | |
| Q3 FY24 | $0.34 | n/a | $1.22 | |
| Q2 FY24 | $0.07 | n/a | $0.42 | |
| Q1 FY24 | $0.37 | n/a | $0.08 | |
| Q4 FY23 | $0.44 | n/a | −$6.15 | |
| Q3 FY23 | −$0.46 | n/a | −$7.83 |
Against its peers
Companies in Drug Manufacturers - General nearest Sarepta Therapeutics' size, closest first, today.
| Company | PE ratio |
|---|---|
| SRPTSarepta Therapeutics | n/m |
| ANIPANI Pharmaceuticals | 15.4× |
| HRMYHarmony Biosciences | 11.7× |
| PAHCPhibro Animal Health | 15.9× |
| PBHPrestige Consumer Healthcare | 13.4× |
| ANABAnaptysbio | 10.7× |
| PCRXPacira BioSciences | 104× |
| NRIXNurix Therapeutics | 11.0× |
| OMEROmeros | 10.9× |
| AMPHAmphastar Pharmaceuticals | 14.8× |
| OGNOrganon | 17.9× |
| Peer median | 14.1× |
What the PE ratio tells you
Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.
Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.
More on Sarepta Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.